Drugs / STX-241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06567015 | Sep 2024 → Nov 2027 expected | non-small cell lung carcinoma | Pierre Fabre Laboratories | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STX-241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567015 ↗ |
| Action | Inhibit | “a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI” NCT06567015 ↗ |
| Modality | Small molecule | “a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI” NCT06567015 ↗ |
| Route | Oral | “Route of administration: Oral” NCT06567015 ↗ |
| Target | EGFR | “a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI” NCT06567015 ↗ |